Continuous infusion of the cannabinoid WIN 55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity

British Journal of Pharmacology

Volumn 151, Issue 2, 2007, Pages 292-302

  Lever, I J ^a   Pheby, T M ^a   Rice, A S C ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Cannabinoid receptor; Nerve injury; Neuropathic pain; WIN 55,212 2

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; CANNABINOID; RIMONABANT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLD SENSITIVITY; CONTINUOUS INFUSION; CONTROLLED STUDY; DATA ANALYSIS; DOSE RESPONSE; IMMUNOHISTOCHEMISTRY; MALE; MECHANICAL STIMULATION; NERVE LIGATION; NEUROPATHIC PAIN; NONHUMAN; OSMOTIC PUMP; PERIPHERAL NERVE INJURY; PRIORITY JOURNAL; RAT; SCIATIC NERVE; SENSORY STIMULATION; WITHDRAWAL REFLEX;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BENZOXAZINES; CANNABINOIDS; COLD; DOSE-RESPONSE RELATIONSHIP, DRUG; INFUSION PUMPS; MALE; MORPHOLINES; NAPHTHALENES; NEURALGIA; PAIN MEASUREMENT; PHYSICAL STIMULATION; PIPERIDINES; PYRAZOLES; RATS; RATS, WISTAR; RECEPTOR, CANNABINOID, CB1; SCIATIC NERVE; TEMPERATURE SENSE; TIME FACTORS;

EID: 34248590393     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707210     Document Type: Article

References (63)

1. Ahluwalia J, Urban L, Bevan S, Nagy I (2003). Anandamide regulates neuropeptide release from capsaicin-sensitive primary sensory neurones by activating both the cannabinoid 1 receptor and the vannilloid receptor 1 in vitro. Eur J Neurosci 17: 2611-2618.
2. Baker D, Pryce G, Croxford JL, Brown P, Pertwee RG, Makriyannis A et al. (2001). Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J 15: 300-302.
3. Baker D, Pryce G, Giovannoni G, Thompson AJ (2003). The therapeutic potential of cannabinoids. Lancet Neurol 2: 291-298.
4. Bell MR, D'Ambra TE, Kumar V, Eissenstat MA, Herrmann JL, Wetzel JR et al. (1991). Anti-nociceptive (aminoalkyl)indoles. J Med Chem 34: 1099-1110.
5. Beltramo M, Bernardini R, Bertorelli M, Campanella E, Nicolussi S, Fredduzzi S et al. (2006). CB2 receptor-mediated antihyperalgesia: possible direct involvement of neural mechanisms. Eur J Neurosci 23: 1530-1538.
6. Bereiter DA, Bereiter DF, Hirata H (2002). Topical cannabinoid agonist, WIN55,212-2, reduces cornea-evoked trigeminal brain-stem activity in the rat. Pain 99: 547-556.
7. Boyd JG, Gordon T (2002). A dose-dependent facilitation and inhibition of peripheral nerve regeneration by brain-derived neurotrophic factor. Eur J Neurosci 15: 613-626.
8. Bridges D, Ahmad KS, Rice ASC (2001). The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a ratmodel of neuropathic pain. Br J Pharmacol 133: 586-594.
9. Bridges D, Rice ASC, Egertova M, Elphick MR, Winter J, Michael GJ (2003). Localisation of cannabinoid receptor 1 in rat dorsal root ganglion using in situ hybridisation and immunohistochemistry. Neuroscience 119: 803-812.
10. Calignano A, La Rana G, Giuffrida A, Piomelli D (1998). Control of pain initiation by endogenous cannabinoids. Nature 394: 277-281.
11. Carlton SM, Lekan HA, Kim SH, Chung JM (1994). Behavioral manifestations of an experimental model for peripheral neuropathy produced by spinal nerve ligation in the primate. Pain 56: 155-166.
12. Costa B, Colleoni M, Conti S, Trovato AE, Bianchi M, Sotgiu ML et al. (2004). Repeated treatment with the synthetic cannabinoid WIN 55,212-2 reduces both hyperalgesia and production of pronociceptive mediators in a rat model of neuropathic pain. Br J Pharmacol 141: 4-8.
13. Dovrak M, Watkinson A, McGlone F, Rukwied R (2003). Histamine induced responses are attenuated by a cannabinoid receptor in human skin. Inflamm Res 52: 238-245.
14. Devor M (2006). Sodium Channels and mechanisms of neuropathic pain. J Pain 7: S3-S12.
15. Elmes SJR, Jhaveri MD, Smart D, Kendall DA, Chapman V (2004). Cannabinoid CB2 receptor activation inhibits mechanically evoked responses of wide dynamic range dorsal horn neurons in naive rats and in rat models of inflammatory and neuropathic pain. Eur J Pharmacol 20: 2311-2320.
16. Ellington HC, Cotter MA, Cameron NE, Ross RA (2002). The effect of cannabinoids on capsaicin-evoked calcitonin gene-related peptide (CGRP) release from the isolated paw skin of diabetic and nondiabetic rats. Neuropharmacology 42: 966-975.
17. Fox A, Kesingland A, Gentry C, McNair K, Patel S, Urban L et al. (2001). The role of central and peripheral cannabinoid1 receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain 92: 91-100.
18. Galve-Roperh I, Sanchez C, Cortes LM, Del Pulgar TG, Izquierdo M, Guzman M (2000). Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nat Med 6: 31-39.
19. Guindon J, Beaulieu P (2006). Antihyperalgesic effects of local injections of anandamide, ibuprofen, rofecoxiib and their combinations in a model of neuropathic pain. Neuropharmacology 50: 814-823.
20. Hasnie FS, Breuer J, Parker S, Wallace VCJ, Blackbeard J, Lever I et al. (2006). Further characterisation of a rat model of varicella zoster virus (VZV)-associated pain: relationship between mechanical hypersensitivity and anxiety-related behaviour; and the influence of analgesic drugs. Neuroscience 144: 1495-1508.
21. Hempenstall K, Nurmikko TJ, Johnson RW, A'Hern R, Rice ASC (2005). Analgesic therapy in postherpetic neuralgia: a quantitative systematic review. PLoS Med 2: 628-644.
22. Henquet C, Krabbendam L, Spauwen J, Kaplan C, Lieb R, Wittchen HU et al. (2005). Prospective cohort study of cannabis use, predisposition for psychosis, and psychotic symptoms in young people. Br Med J 330: 11.
23. Herzberg U, Eliav E, Bennett GJ, Kopin IJ (1997). The analgesic effects of R(+)-WIN55,212-2 mesylate, a high affinity cannabinoid agonist, in a rat model of neuropathic pain. Neurosci Lett 221: 157-160.
24. Ibrahim MM, Deng H, Zvonok A, Cockayne DA, Kwan J, Mata HP et al. (2003). Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci USA 100: 10529-10533.
25. Ibrahim MM, Porreca F, Lai J, Albrecht PJ, Rice FL, Khodortova A et al. (2005). CB-2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci USA 102: 3039-3098.
26. Jaggar SI, Hasnie FS, Sellaturay S, Rice ASC (1998). The antihyperalgesic actions of the cannabinoid anandamide and the putative CB2 agonist palmitoylethanolamide investigated in models of visceral and somatic inflammatory pain. Pain 76: 189-199.
27. Johanek LM, Simone DA (2004). Activation of peripheral cannabinoid receptors attenuates cutaneous hyperalgesia produced by a heat injury. Pain 109: 432-442.
28. 2+ influx in intermediate-size primary afferent neurones of adult rats. Neuroscience 115: 613-625.
29. Kim SH, Chung JM (1992). An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 50: 355-363.
30. Lever IJ, Rice ASC (2006). Cannabinoids. Handbook of Experimental Pharmacology. Springer-Verlag: Berlin, Heidelberg, pp 259-300.
31. Lim G, Sung B, Ji R-R, Mao J (2003). Upregulation of spinal cannabinoid-1-receptors following nerve injury, enhances the effects of Win 55,212-2 on neuropathic pain behaviours in rats. Pain 105: 275-283.
32. Lindenlaub T, Sommer C (2000). Partial sciatic nerve transection as a model of neuropathic pain: a qualitative neuropathological study. Pain 98: 97-106.
33. Mao J, Price DD, Lu J, Keniston L, Mayer DJ (2000). Two distinctive anti-nociceptive systems in rats with pathological pain. Neurosci Lett 280: 13-16.
34. Molina-Holgado F, Pinteaux E, Moore JD, Molina-Holgado E, Guaza C, Gibson RM et al. (2003). Endogenous interleukin-1 receptor antagonist mediates anti-inflammatory and neuroprotective actions of cannabinoids in neurons and glia. J Neurosci 23: 6470-6474.
35. Nackley AG, Suplita II, Hohmann AG (2003). Aperipheral cannabinoid mechanism suppresses spinal fos protein expression and pain behaviour in a rat model of inflammation. Neuroscience 117: 650-670.
36. Nackley AG, Zvonok AM, Makriyannis A, Hohmann AG (2004). Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol 92: 3562-3574.
37. Oka S,Wakui J, GokohM, Kishimoto S, Sugiura T (2006). Suppression by WIN55212-2, a cannabinoid receptor agonist, of inflammatory reactions in mouse ear: Interference with the actions of an endogenous ligand, 2- arachidonoylglycerol. Eur J Pharmacol 538: 154-162.
38. Pascual D, Goicoechea C, Suardiaz M, Martin MI (2005). A cannabinoid agonist WIN55,212-2 reduces neuropathic nociception induced by paclitaxel in rats. Pain 118: 23-34.
39. Pertwee RG (2001). Cannabinoids and pain. Prog Neurobiol 63: 569-611.
40. Pozzi O, Misiano P, Clark GD, Visentin L (2003). Antagonism between the anti-inflammatory activity of the cannabinoid WIN 55212-2 and SR 141716A. Pharmacology 69: 158-163.
41. Pryce G, Ahmed Z, Hankey DJR, Jackson SJ, Croxford JL, Pocock JM et al. (2003). Cannabinoids inhibit neurodegeneration in models of multiple sclerosis. Brain 126: 2191-2202.
42. Puffenbarger R, Boothe AC, Cabral GA (2000). Cannabinoids inhibit LPS-inducible cytokine mRNA expression in rat microglial cells. Glia 29: 58-69.
43. Rice ASC (2005). Cannabinoids. In: Koltzenburg M, McMahon SB (eds). Melzack and Wall: Textbook of Pain. Elsevier: London.
44. Rice ASC, Hill RG (2006). New treatments for neuropathic pain. Ann Rev Med 57: 535-551.
45. Richardson JD, Aanonsen L, Hargreaves KM (1998a). Antihyperalgesic effects of spinal cannabinoids. Eur J Pharmacol 345: 145-153.
46. Richardson JD, Kilo S, Hargreaves KM (1998b). Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. Pain 75: 111-119.
47. Ross RA, Coutts AA, McFarlane SM, Anavi-Goffer S, Irving AJ, Pertwee RG et al. (2001). Actions of cannabinoid receptor ligands on rat cultured sensory neurones: implications for antinociception. Neuropharmacology 40: 221-232.
48. Rukwied R,Watkinson A, McGlone F, Dvorak M (2003). Cannabinoid agonists attenuate capsaicin-induced responses in human skin. Pain 102: 283-288.
49. Sagar DR, Kelly S, Millns PJ, O'Shaughnessey CT, Kendall D, Chapman V (2005). Inhibitory effects on CB1 and CB2 receptor agonists on responses of DRG neurones and dorsal horn neurones in neuropathic rats. Eur J Neurosci 22: 371-379.
50. Savinaninen JR, Kokkola T, Salo OMH, Poso A, Jarvinen T, Laitinen JT (2005). Identification of WIN55212-3 as a competitive neutral antagonist of the human cannabinoid CB2 receptor. Br J Pharmacol 145: 636-645.
51. Scott DA, Wright CE, Angus JA (2004). Evidence that CB-1 and CB-2 cannabinoid receptors mediate antinociception in neuropathic pain in the rat. Pain 109: 124-131.
52. Seltzer Z, Dubner R, Yoram S (1990). A novel behavioural model of neuropathic pain disorders produced in rats by partial sciatic nerve injury. Pain 43: 205-218.
53. Sokal DM, Elmes SJR, Kendall DA, Chapman V (2003). Intraplantar injection of anandamide inhibits mechanically-evoked responses of spinal neurones via activation of CB2 receptors in anaesthetised rats. Neuropharmacology 45: 404-411.
54. Sommer C, Schmidt C, George A (1998). Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1. Exp Neurol 151: 138-142.
55. Song X-J, Zhang J-M, Hu S-J, LaMotte RH (2003). Somata of nerve-injured sensory neurones exhibit enhances responses to inflammtory mediators. Pain 104: 701-709.
56. Ständer S, Schmelz M, Metze D, Luger TM, Rukweid R (2005). Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibres and adnexal structures in human skin. J Dermatol Sci 38: 177-188.
57. Takahashi M, Kawaguchi M, Shimada K, Konishi N, Furuya H, Nakashima T (2004). Peri-sciatic administration of indomethacin early after nerve injury can attenuate the development of tactile allodynia in a rat model of L5 single spinal nerve injury. Neurosci Lett 356: 37-40.
58. Tognetto M, Amadesi S, Harrison S, Creminon C, Trevisani M, Carreras M et al. (2001). Anandamide excites central terminals of dorsal root ganglion neurons via vanilloid receptor-1 activation. J Neurosci 21: 1104-1109.
59. Ulugol A, Karadag HC, Ipci Y, Tarner M, Dokmeci I (2004). The effect of WIN 55,212-2, a cannabinoid agonist, on tactile allodynia in diabetic rats. Neurosci Lett 371: 167-170.
60. Wallace VCJ, McMahon SB, Rice ASC (2005). The Characterisation of Rodent Models of HIV - gp120 and Antiretroviral - Associated Painful Peripheral Neuropathy. 11th World Congress on Pain Abstracts 2005. IASP Press: USA. 67-P44.
61. Walter L, Stella N (2004). Cannabinoids and neuroinflammation. Br J Pharmacol 141: 775-785.
62. Wotherspoon G, Fox A, McIntyre P, Colley S, Bevan S, Winter J (2005). Peripheral nerve injury induces cannabinoid receptor 2 protein expression in rat sensory neurons. Neuroscience 135: 235-245.
63. Zhuang S-Y, Bridges D, Grigorenko E, McCloud S, Boon A, Hampson RE et al. (2005). Cannabinoids produce neuroprotection by reducing intracellular calcium release from ryanodine-sensitive stores. Neuropharmacology 48: 1086-1096.